Rapid intervention with glyceryl trinitrate in hypertensive stroke trial-2 (RIGHT2): assessment of safety and efficacy of transdermal glyceryl trinitrate, a nitric oxide donor, and of the feasibility of a multicentre ambulance-based stroke trial

niversity of Nottingham0 个研究点目标入组 1,149 人开始时间: 2015年3月5日最近更新: 2023年12月12日

适应症

试验速览

2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/30738649 results 2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/28762896 protocol (added 28/11/2019) 2019 Other publications in https://www.ncbi.nlm.nih.gov/pubmed/30475165 baseline characteristics (added 22/01/2020) 2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31587658 results (added 31/03/2020) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36410799/ (added 22/11/2022) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37564156/ 1 year post randomisation (added 14/08/2023) 2023 Results article in https://doi.org/10.1080/10903127.2023.2287171 Narrative data (added 01/12/2023)

•1. Patients presenting to paramedics in context of 999 ambulance call for ‘stroke’
•2. Age 18 years or more (there is no maximum age)
•3. ‘Face/Arm/Speech’ Time (FAST) score >1
•4. Time <=4 hours of onset
•5. Systolic BP >=120 mmHg
•6. Have provided informed consent, or a relative/paramedic has provided proxy consent
•7. Paramedic is trained in RIGHT2 procedures, is from a participating ambulance station and will take patient to a participating comprehensive/primary stroke centre

•1. Patient at a Nursing or Care Home
•2. Glucose (BM stix) <2.5 mmol/l
•3. Glasgow Coma Scale <8
•4. Witnessed seizure/fit at presentation
•5. Known life expectancy <6 months
•6. Known to have taken a PDE5 inhibitor, such as sildenafil, in previous day before stroke
•7. Known sensitivity to Transiderm Nitro patch
•8. Known sensitivity to Duoderm hydrocolloid dressing

发起方

niversity of Nottingham